Design Therapeutics, Inc.
Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.
DSGN | NDAQ
Overview
Corporate Details
- ISIN(s):
- US25056L1035
- LEI:
- Country:
- United States of America
- Address:
- 6005 HIDDEN VALLEY ROAD, 92011 CARLSBAD
- Website:
- https://www.designtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of genomic medicines for serious genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform creates novel, small molecule therapeutic candidates designed to target the underlying cause of genetic disorders. These therapies work by modulating gene expression—either increasing or decreasing it—without requiring gene editing. The company's pipeline is initially focused on monogenic repeat expansion disorders with significant unmet medical need, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington’s disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Design Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Design Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Design Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
